Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04457193
Other study ID # IRB00164823
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date June 7, 2018
Est. completion date June 7, 2027

Study information

Verified date June 2024
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Barrett's esophagus (BE) is a precancerous lesion characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia (IM). Non-dysplastic BE may progress to low-grade dysplasia (LGD), to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). Endoscopic ablation is safe and effective for complete eradication of BE. However, recurrence is common. Cumulative incidence rate of BE recurrence is up to 30% in the third year. Thus, achieving complete eradication of IM, patients should undergo surveillance indefinitely with serial endoscopy to assess for recurrence of BE. In addition, BE patients have been committed to life-long proton pump inhibitor (PPI) therapy, but increasing concerns about adverse effects has led to alternative therapies. Studies have showed that laparoscopic Nissen fundoplication may decrease recurrence of BE after endoscopic ablation. Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date June 7, 2027
Est. primary completion date June 7, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age 18 - 75 years - Known prior diagnosis of histologically-confirmed BE with or without dysplasia (as defined by the presence of specialized columnar epithelium anywhere in the tubular esophagus with >= 1 cm of circumferential involvement or non-circumferential involvement of specialized columnar epithelium) [Prague class >1] and history of initial complete eradication-IM following endoscopic ablation for Barrett's esophagus. - Documentation of complete ablation of BE by endoscopy and histology after radiofrequency or cryotherapy ablation on two endoscopic examinations at least 3 months apart, within most recent endoscopy performed within 6 months. Pathologic diagnosis determined by the expert pathologist at each site. - On PPI therapy, who opt for an intervention over lifelong drug dependence. - Hiatal hernia = 2 cm or Hill grade < 2 [unless patients undergoing combined TIF and hiatal hernia repair] - Abnormal esophageal acid exposure [Percent esophageal acid exposure time > 6% defined by Bravo ph monitoring (48 - 96 hours study) - Able to provide informed consent Exclusion Criteria: - Age < 18 or > 75 years - Inability to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
TIF
Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.

Locations

Country Name City State
United States Saowanee Ngamruengphong Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with normal esophageal acid exposure time Normal esophageal acid exposure time is 6 percent or less. 6 months
Secondary Percentage of participants that are able to discontinue PPI post TIF Percentage of participants that are able to discontinue PPI post TIF will be assessed at 6 months. 6 months
Secondary Incidence of esophagitis post-TIF The presence of esophagitis on upper endoscopy. 6 months
Secondary Proportion of patients with recurrence of BE and BE-related dysplasia Proportion of patients with recurrence of BE and BE-related dysplasia will be assessed up to 36 months. Up to 36 months
Secondary Number of TIF-related serious adverse events Treatment related serious adverse events (SAEs) including hospitalization, unscheduled emergency room or physician visits for post-TIF symptoms), bloating, dysphagia. Up to 36 months
Secondary Change in quality of life as assessed by the GERD-Health-related quality of life Questionnaire The GERD-Health-related quality of life (HRQL) Questionnaire has an overall score range of 0 to 75. Each item is scored from 0 to 5, with a higher score indicating worse symptoms and poorer quality of life. Baseline, 6, 12, 24 and 36 months
Secondary Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI) The RSI is a nine-item self-administered outcome questionnaire designed to document reflux symptoms and severity. Each item is scored on a scale of 0 (no problem) to 5 (severe problem), with overall score ranging between 0 and 45. Higher scores mean more severe symptoms. RSI > 13 may be indicative of significant reflux disease. Baseline, 6, 12, 24 and 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT03554356 - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) N/A
Completed NCT03015389 - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Completed NCT03434834 - OCT Pilot in Esophagus N/A
Terminated NCT04642690 - Nitrates and IL-8 in Barrett's Esophagus
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Completed NCT00217087 - Endoscopic Therapy of Early Cancer in Barretts Esophagus Phase 2
Completed NCT02284802 - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy N/A
Recruiting NCT05530343 - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance N/A
Active, not recruiting NCT04151524 - Classification of Adenocarcinoma of the Esophagogastric Junction
Completed NCT00955019 - Novel Method of Surveillance in Barrett's Esophagus Phase 2
Terminated NCT00386594 - Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus N/A
Completed NCT00576498 - Novel Imaging Techniques in Barrett's Esophagus N/A
Completed NCT02688114 - Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus N/A
Recruiting NCT06071845 - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples N/A
Completed NCT02560623 - A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus N/A
Recruiting NCT05056051 - Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus N/A
Recruiting NCT04001478 - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed NCT03859557 - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed NCT04587310 - Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study